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Summary: Recorded concentrations of the tumour-associated glycoprotein 72 (TAG-72) in ovarian cancer patients
after repeated infusion of the antibody B72.3 were found to be falsely elevated when measured with an homologous
immunometric assay involving the anti-TAG-72 antibody B72.3 (Test 1), or with an heterologous assay involving
CC49 capture and B72.3 detector antibodies (Test 2). Test l yielded falsely elevated values up to l O4 kU/1. Test 2
gave slightly false positive elevations up to 102kU/l for only some of the samples with very high false-positive
values in Test l. The interfering serum components bound to Protein G-Sepharose and could be precipitated with
perchloric acid or by heating serum samples to 100 °C. Addition of non-specific murine immunoglobulins only
partly suppressed false-positive values in both tests. Our results suggest that this interference is caused by human
anti-B72.3 IgG indüced by B72.3 application, which to some extent specifically binds to determinants of the B72.3
antibody. Heat extraction of serum samples effectively eliminated interferences probably caused by anti-idiotypic
antibodies, but did not affect real TAG-72.
Introduction
The monoclonal antibody B72.3 recognises a carbohy-
drate antigen on the tumour-associated glycoprotein 72
(TAG-72) which is expressed in the majority of human
epithelial cancers, including adenocarcinomas of the
stomach and ovary (1—2). Because the antigen is re-
leased into the circulation by tumpurs, monitoring of
senim TAG-72 is used for assessnaent of the course of
disease of patients with gastric cancer (3). Furthermore
it has been proposed äs an additional marker in ovarian
cancer patients (4). The serum concentration of TAG-72
can be measured by mearts of the immunometric "two-
site sandwich" technique using the antibody B723 äs
both the capture and the detector antibody (5), or in an
heterologous assay design with the monoclonal antibody
CC49 (directed against a separate epitope on the TAG-
72 molecule) äs capture antibody, and labelled B72.3
antibody for detection (6).
There have been a number of reports recently suggesting
clinical use of immunoscintigraphy with the monoclonal
antibody B72.3 for the management of patients with
ovarian cancer (7—8). It is well known that a percentage
of patients after exposure to murine immunoglobulins
develop human anti-murine antibodies which can in-
terfere with diagnostic tests using murine antibodies.
Aniong antibodies directed against determinants com-
rnon to all murine antibodies (anti-iso/allotypic), anti-
idiotypic antibodies directed against idiotopes within the
hypervariable region of the applied antibodies can also
be formed (9—10). Anti-iso/allotypic human anti-murine
antibodies interfere with all diagnostic tests involving
murine antibodies (11 — 14). In contrast, anti-idiotypic
human anti-murine antibodies can interfere only in as-
says which use the antibody applied in vivo (or one that
has an antigen binding site which cross-reacts with the
anti-idiotypic human anti-murine antibodies). When this
antibody is employed äs both the capture and the detec-
tor antibody, anti-idiotypic antibodies can cause a falsely
high assay response by cross-linking capture and detec-
tor antibodies (15-16), While interference by anti-iso/
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allotypic human anti-murine antibodies can be elimi-
nated by addition of non-specific murine immunoglobu-
lins (14), interference by anti-idiotypic human anti-mu-
rine antibodies can only be prevented by using capture
(or detector) antibodies different from the antibody ap-
plied in vivo (17).
The aim of the present study was to evaluate the effect
of repeated administration of the antibody B72.3 on the
determination of TAG-72 when a homologous TAG-72
assay involving only B72.3 antibodies, or an heterolo-
gous assay involving CC49 capture and B72.3 detector
antibodies, is used. We detected falsely high results after
B72.3 infiision with both assays, obviously caused by
human anti-B72.3 antibodies. We examined the specific-
ity of the interfering antibodies and established a simple
procedure to eliminate interference, which is suitable for
routine measurement of TAG-72 in patients treated with
the antibody B72.3.
Materials and Methods
Patients and serum samples
All serum samples examined were obtained routinely during follow
up of ovarian cancer patients (Stage II1/IV FIGO). The samples
were aliquoted and stored at —20 °C until analysis.
One hundred and fifty two samples were drawn from 15 patients
who had received one or more inftisions of l mg of the anti-TAG-
72 antibody B72.3 (Oncoscint; Eurocetus, Frankfurt, Germany).
The procedures followed in this study were in accordance with the
Standards of the ethical committee of our faculty. Twenty five sam-
ples drawn from 6 of these patients before antibody treatinent
served äs control. An additional 36 control samples were obtained
from 13 other ovarian cancer patients not treated with murine anti-
bodies.
l ml of serum samples diluted 2-fold with phosphate buffer (0.02
mol/1 sodium phosphate, pH 7.0) to the 3 ml column equilibrated
with phosphate buffer. After 5-minutes incubation at rooxn temper-
ature, the column was washed with 30 ml phosphate buffer to elute
the unadsorbed fraction. The adsorbed IgG fraction was eluted with
15 ml of elution buffer (0.1 mol/1 glycine-HCl, pH 2.7). The eluate
was neutralized immediately with 1.5 ml neutralizing buffer
(l mol/1 tris/hydroxymethyl)-aminornethane-HCl, pH 9.0). Both
the wash fraction äs well äs the eluate were concentrated using
Centricon-30 concentrators (Amicon, Witten, Germany) to a final
volume of 0.5 ml.
Precipitation of serum IgG
To eliminate interfering human antibodies, serum IgG was precipi-
tated with perchloric acid or by a heat extraction procedure.
Precipitation with perchloric acid was carried out accordtng to Kim
et al. (19) with slight modification. Serum (0.4 ml) was diluted
with 0.4 ml NaCl (0.15 mol/1), then mixed with 0.8 ml perchloric
acid (1.2 mol/1). The fesulting precipitate was centrifuged at 1200 g
for 10 min, and l .2 ml of the supernatant was mixed in a separate
test tube with 0.21 ml of a mixture of 8.2 ml KOH (5 mol/1) + 5.0
ml K2HPO4 (3 mol/1). The precipitated KC1O4 was centrifuged at
1200 g for 10 min and the resulting supernatants were stored frozen
at —20 °C until assay. Heat extraction was carried out according
to Kim et al. (20) with slight modification. In disposable glass
tubes, 0.2 ml serum was mixed with 0.4 ml sodium äcetate büffer
(0.2 mol/1 sodium äcetate, pH 5.0). The tubes were covered with
glass beads and incubated for 10 min in a boiling water bath. At
the end of incubation the samples were cooled on ice for 5 min,
then centrifuged at 1200 g for 10 min. The supernatants were stored
frozen at —20 °C until assay.
Blocking of human anti-murine antibodies activity
To block anti-iso/allotypic antibodies, non-specific murine IgG
(Sigma, Deisenhofen, Germany) (OJ01 ml; 16.6 g/l) was added to
the native serum samples (0.24 ml).
Determination of TAG-72
TAG-72 was measured with the B72.3-M-K-S (Test 1; Sorin Bio-
medica, Düsseldorf, Germany) and the ELSA CA 72-4 (Test 2;
Isotopen Diagnostik CIS, Dreieich, Germany). Both tests are solid-
phase immunoradiometric assays for TAG-72. In Test l, the anti-
body B72.3 is used äs both the immobilized and the labelled anti-
body. In Test 2, the monoclonal anti-TAG-72 antibody CC49,
which recognizes a separate epitope on the TAG-72 antigen (18),
is used äs immobilized antibody; the antibody B72.3 serves only
äs detector antibody. In Test l, bindings of both antibodies takes
place simultaneously during a single incubation Step. In Test 2, the
detector antibody is added after all serum components not bound
to the capture antibody have been removed by an additional wash-
ing step. Both tests were performed according to the manufactur-
er's instructions.
Determination of human serum IgG
Human serum IgG was determined by radial immunodifrusion on
LC-Partigen IgG plates (Behring, Marburg, Germany).
Removal of interfering IgG from serum samples
Interfering IgG were removed by affmity chromatography on Pro-
tein G-Sepharose (Pharmacia, Freiburg, Germany). We applied
Statistics and calculation
Linear regression analysis was performed by means of the Passing
& Bablok method (21). As a measure of scatter of data pqints of
the control collective, we calculated the geometric meaa with the
99% tolerance interval for the ratio XI/YI, where Xi and Yj are the
TAG-72 concentrations measured with the respective test kits in
one sample äs previously described (17). A data point (Xa; YJ was
classified äs deviating from the relationship of control samples
when the ratio Xa/Ya exceeded the respective tolerance limits of
the control collective.
Results
Identification of samples containing
interfering antibodies
Serum samples obtained from patients after antibody
treatment were screened for the presence of interfering
anti-B72.3 antibodies by comparing the TAG-7'2 con-
centrations measured with t&e homologous Test l and
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the heterologous Test 2. Figure l shows the results of
TAG-72 determination with the two difFerent tests for
60 control samples together with the respective 99% tol-
erance interval of the ratio Xi/Yi, compared with the
results for 152 samples drawn after antibody treatment.
After antibody treatment, 32% (49/152) of the samples
gave discrepantly high results with Test l compared
with Test 2.
Figure 2 shows the time relationship between the appar-
ent TAG-72 concentrations measured with the homolo-
gous Test l and the heterologous Test 2, respectively,
for a patient with no evidence of disease who received
three antibody infusions. Ten days after the first infu-
sion, the apparent TAG-72 concentration measured with
Test l dramatically increased, while the values measured
with Test 2 did not exceed 5 kU/1. After the second and
the third Infusion, Test l showed additional increases up
to a maximal value of 19 900 kU/1. With Test 2 a slight
apparent increase of TAG-72 up to 88 kU/1 was also
1 10 100 1000 10000
Tumour-Associäted Glycoprotein 72
(heterologous test 2) [kU/l]
Fig. l Comparison of TAG-72 concentrations measured with the
homologous Test l and the heterologous Test 2 in 60 control sam-
ples (P), and in 152 samples obtained from patients treated with
the antibody B72.3 (D). The lines represent the limits of the 99%
tolerance interval of the ratio Xi/Yi calculated for the control col-
lective.
100000
-10 20 50 80 110 140
Time after fifst antibody infusion [days]
Fig. 2 Typical time course of apparent TAG-72 concentration
measured with the homologous Test l (D) and the heterologous
Test 2 (o) during repeated treatment with the antibody B72.3 in a
patient with constant low real TAG-72 concentration. Arrows indi-
cate the time of B72.3 infusions.
measured. The fact that there was no clinical evidence
of disease suggested that the increase of the TAG-72
concentration in both assays was false and that this was
due to anti-B72.3 antibodies formed after infusion of the
antibody B72.3.
To confirm that the observed interferences were indeed
due to human anti-B72.3 antibodies, we attempted to
remove possible interfering antibodies by means of af-
fmity chromatography on protein G-Sepharose (tab. 1):
using two serum samples from two patients after re-
peated antibody infusion, it was found that the TAG-72-
like material reacting with the homologous Test l was
absorbed almost quantitatively by protein G-Sepharose;
77—81% of the applied TAG-72-like material was reco-
vered in the subsequent eluate. Also, the TAG-72-like
material reacting with the heterologous Test 2 was ab-
sorbed, and 80—98% was recovered in the subsequent
eluate. In contrast, when a control sample was used,
70% and 78% of the TAG-72 activity measured with
Test l and Test 2, respectively, passed through the col-
umn, and no TAG-72 activity was found in the subse-
quent eluate. For all samples, serum IgG was absorbed
quantitatively; 82—89% was recovered in the eluate.
Elimination of interfering human anti-B72.3
antibodies
To establish a simple method for the elimination of in-
terfering anti-B72.3 antibodies, we examined heat ex-
traction äs well äs perchloric acid treatment of serum
samples for their effects on interfering antibodies and
real TAG-72. Both procedures effectively eliminated
false positive TAG-72-like activity measured with Test
l äs well äs Test 2 in two samples drawn after treatment
with the antibody B72.3; the TAG-72 concentration of a
control sample was not altered. Serum IgG was removed
completely from all samples (tab. 2).
Because the heat extraction was easier to perform than
the precipitation with perchloric acid, we measured the
TAG-72 concentration of 10 fiirther control samples be-
fore and after heat treatment to validate that this pro-
cedure did not affect real TAG-72. The TAG-72 concen-
trations measured in these samples (Test 1: 18—127
kU/1; Test 2: 11-137 kU/1) were almost completely re-
covered after heat treatment with both Test l (mean re-
covery 97%, ränge 78%-110%) äs well äs Test 2 (mean
recovery 101%, ränge 81%-126%) indicating that the
real TAG-72 concentration was not affected.
Figure 3 shows the effect of heat treatment on the appar-
ent TAG«72 of 11 samples with discrepantly high results
in Test l compared with Test 2. After heating, the appar-
ent TAG-72 concentrations of the samples were reduced
by 65-10400 kU/1 measured with Test l and approxi-
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Tab. 1 Apparent TAG-72 measured with the homologous Test 1 and the heterologous Test 2, and
serum IgG in the fraction from Protein G affmity chromatography.







































































a Drawn from two difFerent patients 10 days after the third (No.
8751) and 79 days after the second (No. 9084) infusion of B72.3
antibody, respectively
b Control patient
n. d., None detected
Tab. 2 Effect of heat extraction and perchloric acid treatment on apparent TAG-72 values measured









































a Drawn from two different patients 70 days after the third (No.
9086) and 112 days after the second (No. 9288) infusion of B72.3
antibody, respectively
b Control patient
n. d., None detected
mately 6-100 kU/1 measured with Test 2. All discrepant
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(heterologous test 2) [kU/l]
Fig. 3 Comparisons of apparent TAG-72 eoncentrations mea-
sured with the homologous Test l and the heterologous Test 2 in
11 discrepant samples before (D) and after (H) heat extraction. the*
lines represent the limits of the 99% tolerance interval of the ratio
i calculated for the control collective.
Specificity of interfering anti-B72.3
antibodies
To examine the Specificity of the interfering IgG we at-
tempted to suppress the falsely high TAG-72 values by
adding increasing amounts of non-specific mouse IgG.
In three serum samples the falsely high TAG-72 values
measured with Test l äs well äs Test 2 were only partly
suppressed by addition of 0.67 g/l non-specific rnouse
IgG (täb. 3); the values measured in control samples
were not affected. When the samples were prediluted to
a TAG-72 concentration in the measuring ränge of Test
l, a maximal reduction of 24—40% was attained with
0.07 g/l mouse IgG. Larger amounts of mouse IgG did
not further redüce the apparent TAG^72 concentration
(fig· 4), indicating the antiidiotypic nature of a high per-
centage of the interfering anti-B72.3 antibodies.
Discussion
This study demonstrates that jn a significant number of
serum samples obtained fromK)varian cancer patients af-
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Tab. 3 Effect of addition of non-specific murine IgG or heat extraction on apparent TAG-72 values






































8 Drawn from three different patients, 70 (No. 9086) and 10 (No. 7103) days after the third and 79
days after the second (No. 9084) infusion of B72.3 antibody, respectively
H 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7
Mouse IgG added [g/l]
Fig. 4 Effect of addition of increasing amounts of non-specific
murine IgG on apparent TAG-72 values measured with the homol-
ogous Test l in serum samples drawn from three different patients
10 (D) and 70 (A) days after the third, and 79 days after the second
(D) infusion of B72.3 antibodies. Apparent TAG-72 of the three
samples was reduced after heat extraction by more than 93%.
ter infusion of the antibody B72.3, falsely high TAG-72
values are measured with an homologous TAG-72 assay
(Test 1) involving only B72.3 antibodies and also to a
lesser degree with an heterologous assay (Test 2) involv-
ing CC49 capture antibodies. The fact that the interfer-
ing agents could be absorbed by protein G and were
precipitated together with serum IgG, äs well äs the rela-
tionship between the time of antibody infusions and the
appearance of interference, strongly suggests that the re-
sponsible serum components are human IgG induced
and boosted by injection of B72;3 antibodies.
The strong interferenee observed with the homologous
Test l is probably caused to a large extent by anti-idio-
typic anti-B72.3 antibodies, which bind specifically to
B72.3 antibodies, and have no or at least only low affin-
ity to the anti-TAG-72 antibody CC49, resulting in only
sldght interference with the heterologous Test 2. This hy-
pothesis is confirrned by the fact that murine IgG only
partly suppressed falsely high values in Test 1. However,
the false positive values, measured with Test 2 in sam-
ples with high false positive TAG-72 values in Test l,
could not be suppressed completely by addition of mu-
rine IgG, suggesting that the CC49 antibodies slightly
cross-react with anti-idiotypic anti-B72.3 antibodies.
Similar interference by anti-idiotypic antibodies has
been observed for the determination of the tumour-asso-
ciated antigen CA 125. In patients treated with the anti-
CA 125 antibody OC125, falsely high CA 125 values
were measured with an homologous assay involving
OC125 äs both capture and detector antibody, which
could not be blocked or absorbed by non-specific murine
IgG (15 — 16). The falsely high values were not observed
when an heterologous assay with a different capture an-
tibody was used (17).
While anti-iso/allotypic human anti-murine antibodies
can be blocked by noh-specific murine IgG, interfer-
ences by anti-idiotypic antibodies can only be elimi-
nated by removing the interfering antibodies. Different
methods are proposed for removing interfering serum
IgG, including affinity chromatography on Protein A,
Protein G or anti-human IgG (13, 15—17), precipitation
with polyethylene glycol (13) or perchloric acid (19),
and heating to 90 °C (13). It has been reported pre-
viously that TAG-72 is heat-stable and soluble in per-
chloric acid (22—23). This is in accordance with our
results, which show that the TAG-72 concentrations
measured in the control samples were not affected by
heating to 100 °C or precipitation with perchloric acid,
whereas interfering human anti-B72.3 was effectively
removed by both procedures. Our data demonstrate that
in samples containing interfering anti-B72.3 antibodies,
the TAG-72 concentration can be determined correctly
after pretreatment by heat extraction. However, the sam-
ples are diluted during heat extraction (3-fold) and pre-
cipitation with perchloric acid (4.7-fold), which
decreases the analytical sensitivity of the measurement.
When the TAG-72 concentration is monitored in patients
treated with the antibody B72.3, one should be aware of
the possibility of interference from newly formed anti-
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B72.3 antibodies. To exclude this interference, samples
obtained after infusion of antibodies should be pre-
treated to remove interfering serum IgG.
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